Molbio Diagnostics IPO
Market Sentiment
IPO Details
IPO Reservation
Financial Analysis
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 840.66 | 1,027.94 | 1,455.17 |
| Expense | 657.83 | 820.41 | 1,221.35 |
| Profit (PAT) | 83.54 | 138.58 | 164.14 |
| Total Assets | 1,221.06 | 1,461.56 | 2,148.42 |
| Company | EPS | P/E | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Poly Medicure Limited | 31.79 | 52.61 | 10.37 | 306.45 | 1,875.26 Cr |
| Dr. Lal Pathlabs Limited | 30.24 | 62.20 | 20.78 | 145.00 | 2,762.91 Cr |
| Metropolis HealthcareLimited | 9.19 | 63.72 | 12.56 | 72.98 | 1,645.85 Cr |
| Vijaya Diagnostics CentreLimited | 16.81 | 81.02 | 18.07 | 93.02 | 814.20 Cr |
Promoters: Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Sriram Natarajan
Strengths & Risks
- Revenue grew 42% in the latest reported year.
- Solid profit margin — 11.3%.
- Strong return on equity — 16%.
Risk signals for Molbio Diagnostics will appear here as subscription, valuation and GMP data arrive. Always read the company-specific risk factors in the RHP before you apply.
Auto-generated from live GMP, subscription, valuation and financial data. Informational only — not investment advice. Always read the RHP before applying.
Company Information
| Purpose | Amount (Cr) |
|---|---|
| Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center of Excellence and connected office space. | 118.08 |
| Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and | 79.04 |
| General corporate purposes | - |
Resources & Documents
Molbio Diagnostics Ltd., Plot No. L-46, Phase II-D, Verna Industrial Area, Verna, Salcete, South Goa, Goa, 403722
Molbio Diagnostics is preparing a mainboard offering. The Mainboard issue is scheduled to open for subscription on August 10, 2026 — 6 days from now.
The issue is promoted by Chandrasekhar Bhaskaran Nair, Exxora Trading LLP, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Sriram Natarajan with Kotak Mahindra Capital Co.Ltd., IIFL Capital Services Ltd., Jefferies India Pvt.Ltd., Motilal Oswal Investment Advisors Ltd. acting as lead manager. Net proceeds will primarily be used towards Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center o… (Rs 118 crore) and Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Uni… (Rs 79 crore).
On fundamentals, the company is posting revenue growth of 41.6%, a profit margin of 11.3%, return on equity of 15.6% in its most recent reported period. Listed peers in this segment include Poly Medicure Limited (P/E 52.61x) and Dr. Lal Pathlabs Limited (P/E 62.20x) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
All figures below — GMP history, subscription tiers, financials and peers — are aggregated from public disclosures. Always apply through your own broker after reading the RHP.
Molbio Diagnostics IPO GMP — What It Means
No active grey market premium has been recorded for Molbio Diagnostics IPO yet. GMP is an unofficial, dealer-quoted indicator of expected listing-day demand — not a guaranteed listing price — and it can change quickly once bidding opens.
See the full Molbio Diagnostics GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!